1 citations
,
November 2021 in “IntechOpen eBooks” Red light therapy may help prevent memory loss as we age.
January 2026 in “International Journal of Molecular Sciences” Hemp's compounds can be used in natural insecticides, cosmetics, and food supplements.
December 2025 in “Clinical and Translational Science” EGFR inhibitors in breast cancer treatment can cause serious skin issues affecting patient quality of life.
November 2025 in “Cancer Cell International” Cancer-associated fibroblasts promote tumor growth in skin cancer.
November 2025 in “Skin Health and Disease” Autosomal recessive woolly hair is rare and involves tightly coiled hair without other health issues.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” LIPH mutations cause woolly hair in some Chinese people.
Allopregnanolone may help reduce inflammation and symptoms related to post-finasteride syndrome.
January 2025 in “Molecules” Caffeine may help with hair loss, but more research is needed to confirm its effectiveness.
September 2023 in “Nature Communications” Rare genetic variants in five specific genes are linked to male-pattern hair loss but only account for a small part of the risk.
June 2023 in “Nephrology Dialysis Transplantation” Enteric hyperoxaluria can cause severe kidney failure after bowel surgery.
March 2026 in “Virulence” Vimentin and keratin help viruses spread and could be targets for antiviral treatments.
Nod factor can trigger changes in legume root hairs with just one molecule.
8 citations
,
August 2025 in “Journal of Translational Medicine” CD44 signaling can help heal wounds without scars.
1 citations
,
January 2021 in “Wits Journal of Clinical Medicine” Long COVID causes lasting symptoms and needs ongoing care.
November 2025 in “Photochemistry and Photobiology” Standardizing light therapy methods could improve spinal cord injury treatment.
October 2025 in “Gene Expression” Exosome therapy could be a promising new way to treat hair loss.
68 citations
,
May 2024 in “International Journal of Molecular Sciences” Personalized acne treatments and new therapies show promise for better results.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
41 citations
,
June 2023 in “Antioxidants” Pomegranate has health benefits and new methods are improving its use in supplements.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
14 citations
,
January 2025 in “Journal of Dermatological Treatment” Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.
7 citations
,
May 2022 in “International Journal of Environmental Research and Public Health” Isotretinoin therapy for acne can cause many reversible side effects, mainly mild skin conditions, and patient understanding of these effects can improve treatment adherence.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
4 citations
,
January 2025 in “JAAD reviews.” Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.
March 2026 in “Immunological Medicine” Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
February 2026 in “The Journal of Dermatology” Ritlecitinib effectively regrows scalp, eyebrow, and eyelash hair in Asians with alopecia areata and is safe.
High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.
September 2025 in “Australasian Journal of Dermatology” New medications could improve treatment for severe alopecia areata in Australia.
Baricitinib is more effective than methotrexate for severe alopecia areata.
March 2025 in “Dermatology” Systemic therapies improve nail psoriasis but have high side effects; more research is needed.